Treatment of intra-abdominal infection with granulocyte colony-stimulating factor

M. O'Reilly, G. M. Silver, David G Greenhalgh, R. L. Gamelli, J. H. Davis, J. C. Hebert

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Polymicrobial infection is a significant cause of mortality in critically ill patients. Antibiotics and surgical intervention are useful but limited in their effectiveness for combating mixed infections. New prophylactic and therapeutic approaches are required to improve survival in critically ill patients. Neutrophils are a known primary host defense mechanism against bacterial infection. We evaluated the use of a neutrophil growth factor, recombinant human granulocyte colony-stimulating factor (G-CSF), to improve survival in a well-established sepsis model, cecal ligation and puncture (CLP). When administered beginning 4 days before CLP with injections continuing for 14 days after CLP, mice that received 10, 100, or 1000 ng of G-CSF had significantly improved survival compared with the control group. When treatment began at the time of CLP and continued for 7 days after CLP, G-CSF treatment resulted in a dose-dependent improvement in survival in groups that received 100, 500, or 1000 ng. The interaction of G-CSF and conventional antimicrobial therapy was evaluated by administration of G-CSF plus gentamicin. Mice received 100 ng of G-CSF beginning on day 1 before CLP with injections continuing for 3 days after CLP. Gentamicin-treated mice received a single 15 mg/kg injection of gentamicin at the time of CLP. Mice that received G-CSF alone or gentamicin alone had significantly improved survival compared with controls. Mice that received G-CSF plus gentamicin had improved survival compared with control mice and compared with mice that received G-CSF alone but not compared with mice that received gentamicin alone. Mice that received G-CSF after CLP had significantly increased numbers of neutrophils compared with mice that received control infections. The ability to augment host defenses by increasing the number and function of neutrophils offers a new possibility for therapeutic intervention to reduce the morbidity and mortality associated with serious infections.

Original languageEnglish (US)
Pages (from-to)679-682
Number of pages4
JournalJournal of Trauma
Volume33
Issue number5
StatePublished - 1992
Externally publishedYes

Fingerprint

Intraabdominal Infections
Granulocyte Colony-Stimulating Factor
Punctures
Ligation
Gentamicins
Survival
Neutrophils
Therapeutics
Coinfection
Critical Illness
Injections
Mortality
Infection Control
Bacterial Infections
Sepsis
Intercellular Signaling Peptides and Proteins
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Surgery

Cite this

O'Reilly, M., Silver, G. M., Greenhalgh, D. G., Gamelli, R. L., Davis, J. H., & Hebert, J. C. (1992). Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. Journal of Trauma, 33(5), 679-682.

Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. / O'Reilly, M.; Silver, G. M.; Greenhalgh, David G; Gamelli, R. L.; Davis, J. H.; Hebert, J. C.

In: Journal of Trauma, Vol. 33, No. 5, 1992, p. 679-682.

Research output: Contribution to journalArticle

O'Reilly, M, Silver, GM, Greenhalgh, DG, Gamelli, RL, Davis, JH & Hebert, JC 1992, 'Treatment of intra-abdominal infection with granulocyte colony-stimulating factor', Journal of Trauma, vol. 33, no. 5, pp. 679-682.
O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. Journal of Trauma. 1992;33(5):679-682.
O'Reilly, M. ; Silver, G. M. ; Greenhalgh, David G ; Gamelli, R. L. ; Davis, J. H. ; Hebert, J. C. / Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. In: Journal of Trauma. 1992 ; Vol. 33, No. 5. pp. 679-682.
@article{f256d327bd004ac288e194ba6605a1b3,
title = "Treatment of intra-abdominal infection with granulocyte colony-stimulating factor",
abstract = "Polymicrobial infection is a significant cause of mortality in critically ill patients. Antibiotics and surgical intervention are useful but limited in their effectiveness for combating mixed infections. New prophylactic and therapeutic approaches are required to improve survival in critically ill patients. Neutrophils are a known primary host defense mechanism against bacterial infection. We evaluated the use of a neutrophil growth factor, recombinant human granulocyte colony-stimulating factor (G-CSF), to improve survival in a well-established sepsis model, cecal ligation and puncture (CLP). When administered beginning 4 days before CLP with injections continuing for 14 days after CLP, mice that received 10, 100, or 1000 ng of G-CSF had significantly improved survival compared with the control group. When treatment began at the time of CLP and continued for 7 days after CLP, G-CSF treatment resulted in a dose-dependent improvement in survival in groups that received 100, 500, or 1000 ng. The interaction of G-CSF and conventional antimicrobial therapy was evaluated by administration of G-CSF plus gentamicin. Mice received 100 ng of G-CSF beginning on day 1 before CLP with injections continuing for 3 days after CLP. Gentamicin-treated mice received a single 15 mg/kg injection of gentamicin at the time of CLP. Mice that received G-CSF alone or gentamicin alone had significantly improved survival compared with controls. Mice that received G-CSF plus gentamicin had improved survival compared with control mice and compared with mice that received G-CSF alone but not compared with mice that received gentamicin alone. Mice that received G-CSF after CLP had significantly increased numbers of neutrophils compared with mice that received control infections. The ability to augment host defenses by increasing the number and function of neutrophils offers a new possibility for therapeutic intervention to reduce the morbidity and mortality associated with serious infections.",
author = "M. O'Reilly and Silver, {G. M.} and Greenhalgh, {David G} and Gamelli, {R. L.} and Davis, {J. H.} and Hebert, {J. C.}",
year = "1992",
language = "English (US)",
volume = "33",
pages = "679--682",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Treatment of intra-abdominal infection with granulocyte colony-stimulating factor

AU - O'Reilly, M.

AU - Silver, G. M.

AU - Greenhalgh, David G

AU - Gamelli, R. L.

AU - Davis, J. H.

AU - Hebert, J. C.

PY - 1992

Y1 - 1992

N2 - Polymicrobial infection is a significant cause of mortality in critically ill patients. Antibiotics and surgical intervention are useful but limited in their effectiveness for combating mixed infections. New prophylactic and therapeutic approaches are required to improve survival in critically ill patients. Neutrophils are a known primary host defense mechanism against bacterial infection. We evaluated the use of a neutrophil growth factor, recombinant human granulocyte colony-stimulating factor (G-CSF), to improve survival in a well-established sepsis model, cecal ligation and puncture (CLP). When administered beginning 4 days before CLP with injections continuing for 14 days after CLP, mice that received 10, 100, or 1000 ng of G-CSF had significantly improved survival compared with the control group. When treatment began at the time of CLP and continued for 7 days after CLP, G-CSF treatment resulted in a dose-dependent improvement in survival in groups that received 100, 500, or 1000 ng. The interaction of G-CSF and conventional antimicrobial therapy was evaluated by administration of G-CSF plus gentamicin. Mice received 100 ng of G-CSF beginning on day 1 before CLP with injections continuing for 3 days after CLP. Gentamicin-treated mice received a single 15 mg/kg injection of gentamicin at the time of CLP. Mice that received G-CSF alone or gentamicin alone had significantly improved survival compared with controls. Mice that received G-CSF plus gentamicin had improved survival compared with control mice and compared with mice that received G-CSF alone but not compared with mice that received gentamicin alone. Mice that received G-CSF after CLP had significantly increased numbers of neutrophils compared with mice that received control infections. The ability to augment host defenses by increasing the number and function of neutrophils offers a new possibility for therapeutic intervention to reduce the morbidity and mortality associated with serious infections.

AB - Polymicrobial infection is a significant cause of mortality in critically ill patients. Antibiotics and surgical intervention are useful but limited in their effectiveness for combating mixed infections. New prophylactic and therapeutic approaches are required to improve survival in critically ill patients. Neutrophils are a known primary host defense mechanism against bacterial infection. We evaluated the use of a neutrophil growth factor, recombinant human granulocyte colony-stimulating factor (G-CSF), to improve survival in a well-established sepsis model, cecal ligation and puncture (CLP). When administered beginning 4 days before CLP with injections continuing for 14 days after CLP, mice that received 10, 100, or 1000 ng of G-CSF had significantly improved survival compared with the control group. When treatment began at the time of CLP and continued for 7 days after CLP, G-CSF treatment resulted in a dose-dependent improvement in survival in groups that received 100, 500, or 1000 ng. The interaction of G-CSF and conventional antimicrobial therapy was evaluated by administration of G-CSF plus gentamicin. Mice received 100 ng of G-CSF beginning on day 1 before CLP with injections continuing for 3 days after CLP. Gentamicin-treated mice received a single 15 mg/kg injection of gentamicin at the time of CLP. Mice that received G-CSF alone or gentamicin alone had significantly improved survival compared with controls. Mice that received G-CSF plus gentamicin had improved survival compared with control mice and compared with mice that received G-CSF alone but not compared with mice that received gentamicin alone. Mice that received G-CSF after CLP had significantly increased numbers of neutrophils compared with mice that received control infections. The ability to augment host defenses by increasing the number and function of neutrophils offers a new possibility for therapeutic intervention to reduce the morbidity and mortality associated with serious infections.

UR - http://www.scopus.com/inward/record.url?scp=0027050458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027050458&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 679

EP - 682

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 5

ER -